Abstract Body

Presentation:

Encouraging data demonstrates that new combination therapies are beginning to achieve HBsAg loss in a significant proportion of chronic hepatitis B (CHB) patients. In some patients, HBsAg loss is durable, achieving functional cure, while others relapse, with HBsAg becoming detectable again during follow up. What determines cure vs. relapse remains unclear but, in the absence of a sterilizing cure, the immune system is believed by many to be a critical component to long-term, off-treatment HBV control. Therefore, immunological adjuvants such as IFN-α, therapeutic vaccines, checkpoint inhibitors, and innate immunomodulators are being/will be combined with novel direct acting antivirals (DAAs) to try and increase the durability of cure. Whether immunomodulation will be a requirement for durable cure, or endogenous immunity will be sufficient, is likely to be patient/cohort specific. This presentation will look at immune correlates of viral control, clinical trials where immunomodulation enhances functional cure rates, and immunological questions that need to be addressed in DAA therapies.